| Year |
Citation |
Score |
| 2024 |
Yang X, Cheng Y, Thall PF, Wahed AS. A generalized outcome-adaptive sequential multiple assignment randomized trial design. Biometrics. 80. PMID 39106124 DOI: 10.1093/biomtc/ujae073 |
0.501 |
|
| 2024 |
Zang Y, Thall PF, Yuan Y. A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison. Biometrics. 80. PMID 38364811 DOI: 10.1093/biomtc/ujad022 |
0.324 |
|
| 2023 |
Msaouel P, Lee J, Thall PF. Risk-benefit trade-offs and precision utilities in phase I-II clinical trials. Clinical Trials (London, England). 17407745231214750. PMID 38111231 DOI: 10.1177/17407745231214750 |
0.388 |
|
| 2023 |
Taniguchi CM, Frakes JM, Aguilera TA, Palta M, Czito B, Bhutani MS, Colbert LE, Abi Jaoude J, Bernard V, Pant S, Tzeng CD, Kim DW, Malafa M, Costello J, Mathew G, ... ... Thall PF, et al. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial. The Lancet. Oncology. 24: 1387-1398. PMID 38039992 DOI: 10.1016/S1470-2045(23)00478-3 |
0.336 |
|
| 2023 |
Msaouel P, Lee J, Thall PF. Interpreting Randomized Controlled Trials. Cancers. 15. PMID 37835368 DOI: 10.3390/cancers15194674 |
0.472 |
|
| 2023 |
Thall PF, Zang Y, Chapple AG, Yuan Y, Lin R, Marin D, Msaouel P. Novel clinical trial designs with dose optimization to improve long-term outcomes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37725573 DOI: 10.1158/1078-0432.CCR-23-2222 |
0.327 |
|
| 2023 |
Jiang L, Thall PF, Yan F, Kopetz S, Yuan Y. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials. Clinical Trials (London, England). 17407745231176445. PMID 37313712 DOI: 10.1177/17407745231176445 |
0.446 |
|
| 2023 |
Thall PF, Zang Y, Yuan Y. Generalized phase I-II designs to increase long term therapeutic success rate. Pharmaceutical Statistics. PMID 37038957 DOI: 10.1002/pst.2301 |
0.399 |
|
| 2023 |
Gladstone DE, D'Alessio FR, Howard C, Lyu MA, Mock JR, Gibbs KW, Abrams D, Huang M, Zeng K, Herlihy JP, Castillo ST, Bassett R, Sadeghi T, Parmar S, Flowers CR, ... ... Thall PF, et al. Randomized, Double Blinded, Placebo Controlled Trial of Allogeneic Cord Blood T-Regulatory Cell for Treatment of COVID-19 ARDS. Blood Advances. PMID 36961352 DOI: 10.1182/bloodadvances.2022009619 |
0.328 |
|
| 2022 |
Lee J, Thall PF, Lim B, Msaouel P. Utility-based Bayesian personalized treatment selection for advanced breast cancer. Journal of the Royal Statistical Society. Series C, Applied Statistics. 71: 1605-1622. PMID 36714159 DOI: 10.1111/rssc.12582 |
0.426 |
|
| 2022 |
Lin R, Shi H, Yin G, Thall PF, Yuan Y, Flowers CR. BAYESIAN HIERARCHICAL RANDOM-EFFECTS META-ANALYSIS AND DESIGN OF PHASE I CLINICAL TRIALS. The Annals of Applied Statistics. 16: 2481-2504. PMID 36329718 DOI: 10.1214/22-aoas1600 |
0.448 |
|
| 2022 |
Thall PF. Adaptive Enrichment Designs in Clinical Trials. Annual Review of Statistics and Its Application. 8: 393-411. PMID 36212769 DOI: 10.1146/annurev-statistics-040720-032818 |
0.487 |
|
| 2022 |
Msaouel P, Lee J, Karam JA, Thall PF. A Causal Framework for Making Individualized Treatment Decisions in Oncology. Cancers. 14. PMID 36010916 DOI: 10.3390/cancers14163923 |
0.41 |
|
| 2022 |
Lee J, Thall PF, Msaouel P. Bayesian Treatment Screening and Selection Using Subgroup-Specific Utilities of Response and Toxicity. Biometrics. PMID 35974457 DOI: 10.1111/biom.13738 |
0.51 |
|
| 2022 |
Qing Y, Thall PF, Yuan Y. A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint. Pharmaceutical Statistics. PMID 35851545 DOI: 10.1002/pst.2256 |
0.381 |
|
| 2021 |
Tidwell RSS, Thall PF, Yuan Y. Lessons Learned From Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer. Jco Precision Oncology. 5. PMID 34805718 DOI: 10.1200/PO.21.00212 |
0.368 |
|
| 2021 |
Lee J, Thall PF, Msaouel P. Precision Bayesian phase I-II dose-finding based on utilities tailored to prognostic subgroups. Statistics in Medicine. PMID 34636054 DOI: 10.1002/sim.9120 |
0.406 |
|
| 2021 |
Lin R, Thall PF, Yuan Y. A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes. Bayesian Analysis. 16: 179-202. PMID 34267857 DOI: 10.1214/20-ba1205 |
0.461 |
|
| 2021 |
Park Y, Liu S, Thall P, Yuan Y. Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers. Biometrics. PMID 33438761 DOI: 10.1111/biom.13421 |
0.427 |
|
| 2020 |
Murray TA, Thall PF, Schortgen F, Asfar P, Zohar S, Katsahian S. Robust Adaptive Incorporation of Historical Control Data in a Randomized Trial of External Cooling to Treat Septic Shock. Bayesian Analysis. 16: 825-844. PMID 36277025 DOI: 10.1214/20-ba1229 |
0.359 |
|
| 2020 |
Lin R, Thall PF, Yuan Y. BAGS: A Bayesian Adaptive Group Sequential Trial Design With Subgroup-Specific Survival Comparisons. Journal of the American Statistical Association. 116: 322-334. PMID 35582047 DOI: 10.1080/01621459.2020.1837142 |
0.394 |
|
| 2020 |
Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U, Alousi AM, Hosing C, Giralt S, Rondon G, Woodworth G, Champlin RE. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Advances. 4: 5580-5588. PMID 33170934 DOI: 10.1182/bloodadvances.2020002544 |
0.378 |
|
| 2020 |
Le-Rademacher JG, Hillman S, Storrick E, Mahoney MR, Thall PF, Jatoi A, Mandrekar SJ. Adverse Event Burden Score-A Versatile Summary Measure for Cancer Clinical Trials. Cancers. 12. PMID 33158080 DOI: 10.3390/cancers12113251 |
0.449 |
|
| 2020 |
Chapple AG, Thall PF. Comparison of Phase I-II designs with parametric or semi-parametric models using two different risk-benefit trade-off criteria. Contemporary Clinical Trials. 97: 106099. PMID 32822828 DOI: 10.1016/j.cct.2020.106099 |
0.357 |
|
| 2020 |
Jiang L, Yan F, Thall PF, Huang X. Comparing Bayesian early stopping boundaries for phase II clinical trials. Pharmaceutical Statistics. PMID 32720462 DOI: 10.1002/pst.2046 |
0.45 |
|
| 2019 |
Thall PF. Bayesian Utility-Based Designs for Subgroup-Specific Treatment Comparison and Early-Phase Dose Optimization in Oncology Clinical Trials. Jco Precision Oncology. 3. PMID 33015521 DOI: 10.1200/PO.18.00379 |
0.495 |
|
| 2019 |
Thall PF. Bayesian Cancer clinical trial designs with subgroup-specific decisions. Contemporary Clinical Trials. 105860. PMID 31678411 DOI: 10.1016/j.cct.2019.105860 |
0.447 |
|
| 2019 |
Lin R, Thall PF, Yuan Y. An Adaptive Trial Design to Optimize Dose--Schedule Regimes with Delayed Outcomes. Biometrics. PMID 31273750 DOI: 10.1111/Biom.13116 |
0.45 |
|
| 2019 |
Chapple AG, Thall PF. Rejoinder to "A hybrid phase I-II/III clinical trial design allowing dose reoptimization in phase III". Biometrics. PMID 31245839 DOI: 10.1111/biom.12991 |
0.354 |
|
| 2019 |
Lee J, Thall PF, Rezvani K. Optimizing natural killer cell doses for heterogeneous cancer patients on the basis of multiple event times. Journal of the Royal Statistical Society. Series C, Applied Statistics. 68: 461-474. PMID 31105345 DOI: 10.1111/rssc.12271 |
0.342 |
|
| 2019 |
Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, et al. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. The Lancet. Haematology. PMID 30910541 DOI: 10.1016/S2352-3026(19)30023-7 |
0.317 |
|
| 2019 |
Boulet S, Ursino M, Thall P, Jannot AS, Zohar S. Bayesian variable selection based on clinical relevance weights in small sample studies-Application to colon cancer. Statistics in Medicine. PMID 30672015 DOI: 10.1002/sim.8107 |
0.302 |
|
| 2019 |
Gauthier J, Yuan Y, Thall P. Bayesian Phase 1/2 trial designs and cellular immunotherapies: a practical primer Cell and Gene Therapy Insights. 5: 1483-1494. DOI: 10.18609/cgti.2019.152 |
0.392 |
|
| 2018 |
Chapple AG, Thall PF. A Hybrid Phase I-II/III Clinical Trial Design Allowing Dose Re-Optimization in Phase III. Biometrics. PMID 30367457 DOI: 10.1111/biom.12994 |
0.349 |
|
| 2018 |
Chapple AG, Thall PF. Subgroup-specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combination. Pharmaceutical Statistics. PMID 30112806 DOI: 10.1002/pst.1891 |
0.396 |
|
| 2018 |
Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, et al. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem-Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29501779 DOI: 10.1016/J.Bbmt.2018.02.020 |
0.345 |
|
| 2018 |
Murray TA, Yuan Y, Thall PF, Elizondo JH, Hofstetter WL. A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups. Biometrics. PMID 29359314 DOI: 10.1111/Biom.12842 |
0.464 |
|
| 2017 |
Müller P, Xu Y, Thall PF. Clinical Trial Design as a Decision Problem. Applied Stochastic Models in Business and Industry. 33: 296-301. PMID 29200977 DOI: 10.1002/Asmb.2222 |
0.362 |
|
| 2017 |
Wathen JK, Thall PF. A simulation study of outcome adaptive randomization in multi-arm clinical trials. Clinical Trials (London, England). 14: 432-440. PMID 28982263 DOI: 10.1177/1740774517692302 |
0.775 |
|
| 2017 |
Xu Y, Thall PF, Müller P, Mehran RJ. A Decision-Theoretic Comparison of Treatments to Resolve Air Leaks After Lung Surgery Based on Nonparametric Modeling. Bayesian Analysis. 12: 639-652. PMID 28959372 DOI: 10.1214/16-Ba1016 |
0.336 |
|
| 2017 |
Murray TA, Thall PF, Yuan Y, McAvoy S, Gomez DR. Robust treatment comparison based on utilities of semi-competing risks in non-small-cell lung cancer. Journal of the American Statistical Association. 112: 11-23. PMID 28943681 DOI: 10.1080/01621459.2016.1176926 |
0.396 |
|
| 2017 |
Thall PF, Ursino M, Baudouin V, Alberti C, Zohar S. Bayesian treatment comparison using parametric mixture priors computed from elicited histograms. Statistical Methods in Medical Research. 962280217726803. PMID 28870123 DOI: 10.1177/0962280217726803 |
0.378 |
|
| 2017 |
Thall PF, Mueller P, Xu Y, Guindani M. Bayesian nonparametric statistics: A new toolkit for discovery in cancer research. Pharmaceutical Statistics. PMID 28677272 DOI: 10.1002/pst.1819 |
0.442 |
|
| 2017 |
Thall PF, Nguyen HQ, Zinner RG. Parametric Dose Standardization for Optimizing Two-Agent Combinations in a Phase I-II Trial with Ordinal Outcomes. Journal of the Royal Statistical Society. Series C, Applied Statistics. 66: 201-224. PMID 28255183 DOI: 10.1111/rssc.12162 |
0.339 |
|
| 2017 |
Morita S, Thall PF, Takeda K. A simulation study of methods for selecting subgroup-specific doses in phase 1 trials. Pharmaceutical Statistics. PMID 28111916 DOI: 10.1002/pst.1797 |
0.388 |
|
| 2017 |
Ursino M, Thall P, Alberti C, Zohar S. Bayesian treatment comparison using parametric mixture priors based on histograms elicited from expert physicians Revue D'éPidéMiologie Et De Santé Publique. 65: S59-S60. DOI: 10.1016/J.Respe.2017.03.028 |
0.463 |
|
| 2016 |
Xu Y, Müller P, Wahed AS, Thall PF. Bayesian Nonparametric Estimation for Dynamic Treatment Regimes with Sequential Transition Times. Journal of the American Statistical Association. 111: 921-935. PMID 28018015 DOI: 10.1080/01621459.2015.1086353 |
0.4 |
|
| 2016 |
Murray TA, Thall PF, Yuan Y. Utility-based designs for randomized comparative trials with categorical outcomes. Statistics in Medicine. PMID 27189672 DOI: 10.1002/Sim.6989 |
0.421 |
|
| 2016 |
Hobbs BP, Thall PF, Lin SH. Bayesian Group Sequential Clinical Trial Design using Total Toxicity Burden and Progression-Free Survival. Journal of the Royal Statistical Society. Series C, Applied Statistics. 65: 273-297. PMID 27034510 DOI: 10.1111/Rssc.12117 |
0.366 |
|
| 2016 |
Thall PF, Nguyen HQ, Zinner RG. Parametric dose standardization for optimizing two-agent combinations in a phase I-II trial with ordinal outcomes Journal of the Royal Statistical Society. Series C: Applied Statistics. DOI: 10.1111/rssc.12162 |
0.345 |
|
| 2016 |
Hobbs BP, Thall PF, Lin SH. Bayesian group sequential clinical trial design using total toxicity burden and progression-free survival Journal of the Royal Statistical Society. Series C: Applied Statistics. 65: 273-297. DOI: 10.1111/rssc.12117 |
0.386 |
|
| 2015 |
Lee J, Thall PF, Ji Y, Müller P. A decision-theoretic phase I-II design for ordinal outcomes in two cycles. Biostatistics (Oxford, England). PMID 26553915 DOI: 10.1093/Biostatistics/Kxv045 |
0.366 |
|
| 2015 |
Lee J, Thall PF, Ji Y, Müller P. Bayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and Toxicity. Journal of the American Statistical Association. 110: 711-722. PMID 26366026 DOI: 10.1080/01621459.2014.926815 |
0.327 |
|
| 2015 |
Thall P, Fox P, Wathen J. Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 1621-8. PMID 25979922 DOI: 10.1093/annonc/mdv238 |
0.769 |
|
| 2015 |
Graziani R, Guindani M, Thall PF. Bayesian nonparametric estimation of targeted agent effects on biomarker change to predict clinical outcome. Biometrics. 71: 188-97. PMID 25319212 DOI: 10.1111/biom.12250 |
0.328 |
|
| 2014 |
Jin IH, Liu S, Thall PF, Yuan Y. Using Data Augmentation to Facilitate Conduct of Phase I-II Clinical Trials with Delayed Outcomes. Journal of the American Statistical Association. 109: 525-536. PMID 25382884 DOI: 10.1080/01621459.2014.881740 |
0.491 |
|
| 2013 |
Wahed AS, Thall PF. Evaluating Joint Effects of Induction-Salvage Treatment Regimes on Overall Survival in Acute Leukemia. Journal of the Royal Statistical Society. Series C, Applied Statistics. 62: 67-83. PMID 24014891 DOI: 10.1111/J.1467-9876.2012.01048.X |
0.408 |
|
| 2013 |
Thall PF, Nguyen HQ, Braun TM, Qazilbash MH. Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes. Biometrics. 69: 673-82. PMID 23957592 DOI: 10.1111/biom.12065 |
0.32 |
|
| 2013 |
Wahed AS, Thall PF. Evaluating joint effects of induction-salvage treatment regimes on overall survival in acute leukaemia Journal of the Royal Statistical Society. Series C: Applied Statistics. 62: 67-83. DOI: 10.1111/j.1467-9876.2012.01048.x |
0.414 |
|
| 2012 |
Morita S, Thall PF, Müller P. Prior Effective Sample Size in Conditionally Independent Hierarchical Models. Bayesian Analysis (Online). 7. PMID 24175005 DOI: 10.1214/12-Ba720 |
0.41 |
|
| 2012 |
Wang L, Rotnitzky A, Lin X, Millikan RE, Thall PF. Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer. Journal of the American Statistical Association. 107: 493-508. PMID 22956855 DOI: 10.1080/01621459.2011.641416 |
0.486 |
|
| 2012 |
Thall PF, Nguyen HQ. Adaptive randomization to improve utility-based dose-finding with bivariate ordinal outcomes. Journal of Biopharmaceutical Statistics. 22: 785-801. PMID 22651115 DOI: 10.1080/10543406.2012.676586 |
0.322 |
|
| 2012 |
Thall PF, Nguyen HQ, Wang X, Wolff JE. A Hybrid Geometric Phase II/III Clinical Trial Design based on Treatment Failure Time and Toxicity. Journal of Statistical Planning and Inference. 142: 944-955. PMID 22228921 DOI: 10.1016/j.jspi.2011.10.016 |
0.458 |
|
| 2012 |
Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer. 118: 2507-15. PMID 21887685 DOI: 10.1002/cncr.26517 |
0.349 |
|
| 2011 |
Thall PF, Szabo A, Nguyen HQ, Amlie-Lefond CM, Zaidat OO. Optimizing the concentration and bolus of a drug delivered by continuous infusion. Biometrics. 67: 1638-46. PMID 21401568 DOI: 10.1111/J.1541-0420.2011.01580.X |
0.381 |
|
| 2010 |
Thall PF. Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials. Statistical Science : a Review Journal of the Institute of Mathematical Statistics. 25: 227-244. PMID 21318084 DOI: 10.1214/09-STS315 |
0.513 |
|
| 2010 |
Morita S, Thall PF, Müller P. Evaluating the Impact of Prior Assumptions in Bayesian Biostatistics. Statistics in Biosciences. 2: 1-17. PMID 20668651 DOI: 10.1007/S12561-010-9018-X |
0.495 |
|
| 2010 |
Moulder SL, Holmes FA, Tolcher AW, Thall P, Broglio K, Valero V, Buzdar AU, Arbuck SG, Seidman A, Hortobagyi GN. A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer. Cancer. 116: 814-21. PMID 20052721 DOI: 10.1002/cncr.24870 |
0.331 |
|
| 2010 |
Houede N, Thall PF, Nguyen H, Paoletti X, Kramar A. Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials. Biometrics. 66: 532-40. PMID 19673865 DOI: 10.1111/j.1541-0420.2009.01302.x |
0.463 |
|
| 2009 |
Thall PF. Discussion on "A Hybrid Selection and Testing Procedure with Curtailment for Comparative Clinical Trials" by Elena M. Buzaianu and Pinyuen Chen. Sequential Analysis. 28: 41-43. PMID 20622929 DOI: 10.1080/07474940802619170 |
0.374 |
|
| 2009 |
Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, Dinney CP, Millikan RE. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2592-7. PMID 19414678 DOI: 10.1200/JCO.2008.19.0256 |
0.381 |
|
| 2008 |
Wathen JK, Thall PF. Bayesian adaptive model selection for optimizing group sequential clinical trials. Statistics in Medicine. 27: 5586-604. PMID 18752257 DOI: 10.1002/sim.3381 |
0.732 |
|
| 2008 |
Thall PF, Wathen JK. Bayesian designs to account for patient heterogeneity in phase II clinical trials. Current Opinion in Oncology. 20: 407-11. PMID 18525336 DOI: 10.1097/CCO.0b013e328302163c |
0.764 |
|
| 2008 |
Thall PF, Nguyen HQ, Estey EH. Patient-specific dose finding based on bivariate outcomes and covariates. Biometrics. 64: 1126-36. PMID 18355387 DOI: 10.1111/j.1541-0420.2008.01009.x |
0.326 |
|
| 2008 |
Bekele BN, Ji Y, Shen Y, Thall PF. Monitoring late-onset toxicities in phase I trials using predicted risks. Biostatistics (Oxford, England). 9: 442-57. PMID 18084008 DOI: 10.1093/biostatistics/kxm044 |
0.317 |
|
| 2008 |
Wathen JK, Thall PF, Cook JD, Estey EH. Accounting for patient heterogeneity in phase II clinical trials. Statistics in Medicine. 27: 2802-15. PMID 17948869 DOI: 10.1002/sim.3109 |
0.777 |
|
| 2008 |
Thall PF. A review of phase 2-3 clinical trial designs. Lifetime Data Analysis. 14: 37-53. PMID 17763973 DOI: 10.1007/s10985-007-9049-x |
0.389 |
|
| 2007 |
Thall PF, Logothetis C, Pagliaro LC, Wen S, Brown MA, Williams D, Millikan RE. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. Journal of the National Cancer Institute. 99: 1613-22. PMID 17971530 DOI: 10.1093/jnci/djm189 |
0.37 |
|
| 2007 |
Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, Thall PF, Benjamin RS, Baker LH, Hensley ML. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 2755-63. PMID 17602081 DOI: 10.1200/JCO.2006.10.4117 |
0.741 |
|
| 2007 |
Braun TM, Thall PF, Nguyen H, de Lima M. Simultaneously optimizing dose and schedule of a new cytotoxic agent. Clinical Trials (London, England). 4: 113-24. PMID 17456511 DOI: 10.1177/1740774507076934 |
0.341 |
|
| 2007 |
Thall PF, Wooten LH, Logothetis CJ, Millikan RE, Tannir NM. Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Statistics in Medicine. 26: 4687-702. PMID 17427204 DOI: 10.1002/sim.2894 |
0.414 |
|
| 2007 |
Thall PF, Wathen JK. Practical Bayesian adaptive randomisation in clinical trials. European Journal of Cancer (Oxford, England : 1990). 43: 859-66. PMID 17306975 DOI: 10.1016/j.ejca.2007.01.006 |
0.762 |
|
| 2007 |
Thall PF, Cheung YK, Inoue LYT, Wathen JK. Comments on 'Continuous Bayesian adaptive randomization based on event times with covariates' [4] Statistics in Medicine. 26: 3052-3054. DOI: 10.1002/Sim.2762 |
0.701 |
|
| 2006 |
Maki RG, Hensley ML, Wathen JK, Patel SR, Priebat DA, Okuno S, Reinke D, Thall PF, Benjamin RS, Baker LH. A SARC multicenter phase III study of gemcitabine (G) vs. gemcitabine and docetaxel (G+D) in patients (pts) with metastatic soft tissue sarcomas (STS). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 9514. PMID 27952836 DOI: 10.1200/jco.2006.24.18_suppl.9514 |
0.678 |
|
| 2006 |
Thall PF, Cook JD, Estey EH. Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations. Journal of Biopharmaceutical Statistics. 16: 623-38. PMID 17037262 DOI: 10.1080/10543400600860394 |
0.442 |
|
| 2006 |
Thall PF, Estey EH, Markman M. Some ethical issues in phase II trials in acute leukemia. Clinical Advances in Hematology & Oncology : H&O. 4: 95. PMID 16739255 |
0.344 |
|
| 2006 |
Thall PF, Wooten LH, Shpall EJ. A geometric approach to comparing treatments for rapidly fatal diseases. Biometrics. 62: 193-201. PMID 16542246 DOI: 10.1111/j.1541-0420.2005.00434.x |
0.337 |
|
| 2006 |
Cheung YK, Inoue LY, Wathen JK, Thall PF. Continuous Bayesian adaptive randomization based on event times with covariates. Statistics in Medicine. 25: 55-70. PMID 16025549 DOI: 10.1002/Sim.2247 |
0.777 |
|
| 2006 |
Mathew P, Thall PF, Johnson MM, Oh WK, Meluch AA, Morris MJ, Troncoso P, Bucana CD, Fidler IJ, Logothetis CJ. Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM) Journal of Clinical Oncology. 24: 4562-4562. DOI: 10.1200/Jco.2006.24.18_Suppl.4562 |
0.301 |
|
| 2006 |
Bekele BN, Thall PF. Dose-Finding Based on Multiple Ordinal Toxicities in Phase I Oncology Trials Statistical Methods For Dose-Finding Experiments. 243-258. DOI: 10.1002/0470861258.ch12 |
0.332 |
|
| 2005 |
Thall PF, Estey EH. Some ethical issues in phase II trials in acute leukemia. Clinical Advances in Hematology & Oncology : H&O. 3: 943-8. PMID 16555436 |
0.491 |
|
| 2005 |
Thall PF, Wooten LH, Tannir NM. Monitoring event times in early phase clinical trials: some practical issues. Clinical Trials (London, England). 2: 467-78. PMID 16422307 DOI: 10.1191/1740774505cn121oa |
0.425 |
|
| 2005 |
Braun TM, Yuan Z, Thall PF. Determining a maximum-tolerated schedule of a cytotoxic agent. Biometrics. 61: 335-43. PMID 16011679 DOI: 10.1111/j.1541-0420.2005.00312.x |
0.429 |
|
| 2005 |
Thall PF, Wathen JK. Covariate-adjusted adaptive randomization in a sarcoma trial with multi-stage treatments. Statistics in Medicine. 24: 1947-64. PMID 15806621 DOI: 10.1002/sim.2077 |
0.763 |
|
| 2004 |
Millikan RE, Thall P, Pagliaro L, Williams D, Brown M, Logothetis C. Randomized, adaptive, phase II selection trial of four chemotherapy regimens in androgen independent prostate cancer (AIPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 4561. PMID 28015942 DOI: 10.1200/jco.2004.22.14_suppl.4561 |
0.444 |
|
| 2004 |
Thall PF, Cook JD. Dose-finding based on efficacy-toxicity trade-offs. Biometrics. 60: 684-93. PMID 15339291 DOI: 10.1111/j.0006-341X.2004.00218.x |
0.399 |
|
| 2004 |
Siefker-Radtke AO, Thall PF, Tannir NM, Tu S, Pagliaro LC, Williams DL, Millikan RE. Implementation of a novel statistical design to evaluate successive treatment courses for metastatic transitional cell carcinoma. A Phase II trial at the M. D. Anderson Cancer Center Journal of Clinical Oncology. 22: 4543-4543. DOI: 10.1200/jco.2004.22.90140.4543 |
0.339 |
|
| 2003 |
Thall PF, Millikan RE, Mueller P, Lee SJ. Dose-finding with two agents in Phase I oncology trials. Biometrics. 59: 487-96. PMID 14601749 DOI: 10.1111/1541-0420.00058 |
0.368 |
|
| 2003 |
Thall PF, Lee SJ. Practical model-based dose-finding in phase I clinical trials: Methods based on toxicity International Journal of Gynecological Cancer. 13: 251-261. PMID 12801254 DOI: 10.1046/j.1525-1438.2003.13202.x |
0.383 |
|
| 2003 |
Thall PF, Wathen JK, Bekele BN, Champlin RE, Baker LH, Benjamin RS. Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. Statistics in Medicine. 22: 763-80. PMID 12587104 DOI: 10.1002/sim.1399 |
0.75 |
|
| 2003 |
Estey EH, Thall PF. New designs for phase 2 clinical trials. Blood. 102: 442-8. PMID 12560224 DOI: 10.1182/blood-2002-09-2937 |
0.537 |
|
| 2002 |
Inoue LY, Thall PF, Berry DA. Seamlessly expanding a randomized phase II trial to phase III. Biometrics. 58: 823-31. PMID 12495136 |
0.444 |
|
| 2002 |
Thall PF, Inoue LY, Martin TG. Adaptive decision making in a lymphocyte infusion trial. Biometrics. 58: 560-8. PMID 12229990 |
0.418 |
|
| 2002 |
Cheung YK, Thall PF. Monitoring the rates of composite events with censored data in phase II clinical trials. Biometrics. 58: 89-97. PMID 11890331 DOI: 10.1111/J.0006-341X.2002.00089.X |
0.51 |
|
| 2002 |
Thall PF, Sung HG, Estey EH. Selecting therapeutic strategies based on efficacy and death in multicourse clinical trials Journal of the American Statistical Association. 97: 29-39. DOI: 10.1198/016214502753479202 |
0.364 |
|
| 2001 |
Stallard N, Thall PF. Decision-theoretic designs for pre-phase II screening trials in oncology Biometrics. 57: 1089-1095. PMID 11764248 |
0.418 |
|
| 2001 |
Thall PF, Sung HG, Choudhury A. Dose-finding based on feasibility and toxicity in T-cell infusion trials Biometrics. 57: 914-921. PMID 11550945 |
0.363 |
|
| 2001 |
Thall PF, Cheng SC. Optimal two-stage designs for clinical trials based on safety and efficacy Statistics in Medicine. 20: 1023-1032. PMID 11276033 DOI: 10.1002/sim.717 |
0.482 |
|
| 2001 |
Thall PF. Bayesian Clinical Trial Design in a Cancer Center Chance. 14: 23-28. DOI: 10.1080/09332480.2001.10542279 |
0.364 |
|
| 2000 |
Thall PF, Millikan RE, Sung HG. Evaluating multiple treatment courses in clinical trials Statistics in Medicine. 19: 1011-1028. PMID 10790677 DOI: 10.1002/(SICI)1097-0258(20000430)19:8<1011::AID-SIM414>3.0.CO;2-M |
0.536 |
|
| 2000 |
Thall PF, Simon RM, Shen Y. Approximate Bayesian evaluation of multiple treatment effects Biometrics. 56: 213-219. PMID 10783798 |
0.393 |
|
| 1999 |
Stallard N, Thall PF, Whitehead J. Decision theoretic designs for phase II clinical trials with multiple outcomes Biometrics. 55: 971-977. PMID 11315037 |
0.443 |
|
| 1999 |
Thall PF, Cheng SC. Treatment comparisons based on two-dimensional safety and efficacy alternatives in oncology trials Biometrics. 55: 746-753. PMID 11315002 |
0.325 |
|
| 1999 |
Thall PF, Estey EH, Sung HG. A new statistical method for dose-finding based on efficacy and toxicity in early phase clinical trials Investigational New Drugs. 17: 155-167. PMID 10638486 DOI: 10.1023/A:1006323317135 |
0.443 |
|
| 1999 |
Thall PF, Lee JJ, Tseng CH, Estey EH. Accrual strategies for phase I trials with delayed patient outcome Statistics in Medicine. 18: 1155-1169. PMID 10363337 DOI: 10.1002/(SICI)1097-0258(19990530)18:10<1155::AID-SIM114>3.0.CO;2-H |
0.48 |
|
| 1998 |
Thall PF, Sung HG. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials Statistics in Medicine. 17: 1563-1580. PMID 9699230 DOI: 10.1002/(SICI)1097-0258(19980730)17:14<1563::AID-SIM873>3.0.CO;2-L |
0.518 |
|
| 1998 |
Thall PF, Russell KE. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials Biometrics. 54: 251-264. PMID 9544520 DOI: 10.2307/2534012 |
0.487 |
|
| 1997 |
Staniswalis JG, Thall PF, Salch J. Semiparametric regression analysis for recurrent event interval counts Biometrics. 53: 1334-1353. PMID 9423253 DOI: 10.2307/2533501 |
0.348 |
|
| 1997 |
Estey E, Thall P, David C. Design and analysis of trials of salvage therapy in acute myelogenous leukemia. Cancer Chemotherapy and Pharmacology. S9-12. PMID 9272127 DOI: 10.1007/s002800051054 |
0.326 |
|
| 1996 |
Thall PF, Simon RM, Estey EH. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials Journal of Clinical Oncology. 14: 296-303. PMID 8558211 |
0.507 |
|
| 1995 |
Thall PF, Simon RM, Estey EH. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes Statistics in Medicine. 14: 357-379. PMID 7746977 |
0.477 |
|
| 1995 |
Thall PF, Simon RM. Recent developments in the design of phase II clinical trials Cancer Treatment and Research. 75: 49-71. PMID 7640167 |
0.408 |
|
| 1994 |
Simon R, Thall PF, Ellenberg SS. New designs for the selection of treatments to be tested in randomized clinical trials Statistics in Medicine. 13: 417-429. PMID 8023026 DOI: 10.1002/Sim.4780130506 |
0.496 |
|
| 1994 |
Thall PF, Simon R. Practical Bayesian guidelines for phase IIB clinical trials Biometrics. 50: 337-349. PMID 7980801 DOI: 10.2307/2533377 |
0.423 |
|
| 1994 |
Thall PF, Simon R. A Bayesian approach to establishang sample size and monitoring criteria for phase II clinical trials Controlled Clinical Trials. 15: 463-481. PMID 7851108 DOI: 10.1016/0197-2456(94)90004-3 |
0.46 |
|
| 1994 |
Thall PF, Simon RM, Estey EH. 17A Bayesian designs for clinical trials with multiple endpoints Controlled Clinical Trials. 15: 43. DOI: 10.1016/0197-2456(94)90078-7 |
0.341 |
|
| 1993 |
Thall PF, Simon R. A61 Sample size and monitoring criteria for Bayesian phase II clinical trials Controlled Clinical Trials. 14: 424. DOI: 10.1016/0197-2456(93)90127-Y |
0.339 |
|
| 1992 |
Thall PF, Simon R. Bayesian guidelines for phase II clinical trial design and analysis Controlled Clinical Trials. 13: 377. |
0.433 |
|
| 1990 |
Thall PF, Simon R. Incorporating historical control data in planning phase II clinical trials Statistics in Medicine. 9: 215-228. PMID 2188324 |
0.494 |
|
| 1989 |
Thall PF, Simon R, Ellenberg SS. A two-stage design for choosing among several experimental treatments and a control in clinical trials Biometrics. 45: 537-547. PMID 2765637 DOI: 10.2307/2531495 |
0.423 |
|
| 1988 |
Thall PF, Simon R, Ellenberg SS. Two-stage selection and testing designs for comparative clinical trials Biometrika. 75: 303-310. DOI: 10.1093/Biomet/75.2.303 |
0.308 |
|
| 1988 |
Thall PF, Lachin JM. Analysis of recurrent events: Nonparametric methods for random-interval count data Journal of the American Statistical Association. 83: 339-347. DOI: 10.1080/01621459.1988.10478603 |
0.375 |
|
| 1988 |
Thall PF, Simon R, Ellenberg SS, Shrager. Optimal two-stage designs for clinical trials with binary response Controlled Clinical Trials. 9: 252. DOI: 10.1016/0197-2456(88)90100-6 |
0.356 |
|
| 1988 |
Thall PF, Simon R, Ellenberg SS, Shrager. Optimal two-stage designs for clinical trials with binary response Controlled Clinical Trials. 9: 252. |
0.356 |
|
| Show low-probability matches. |